Study on the relationship between the Bcl-2/Bax ratio and the growth types of leukemic cells and drug resistance in acute myelogenous leukemia

Abstract

The ratio of Bcl-2 to Bax (Bcl-2/Bax) in 40 patients with acute myelogenous leukemia (AMD were determined. At the same time, the CFU-L of AML patients and drug resistance were detected by cell culture and MTT assay. The results showed that Bcl-2/Bax in AML was significantly higher than that in normal control (P<0.001). Bcl-2/Bax ratio in colony growth group was higher than that in no-growth group (P <0. 05). Between drug resistance group and drug sensitivity group there was a significant difference in Bcl-2/Bax ratio (P <0. 05). There were more cases of drug resistance in high ratio group (H) than in low ratio group (L) (P <0.05). Meanwhile, Complete Remission (CR) rate in group H was obviously lower than that in group L (P <0.05) and patients in group H tended to have poor response. The above results indicated that the alteration of Bcl-2 and Bax is an important mechanism in the pathogenesis, progress and the development of drug resistance in AML. The determination of Bcl-2/Bax ratio has far-reaching implication in the treatment, choice of chemotherapeutic agents, and prediction of prognosis.

Keywords

acute myelogenous leukemia / Bcl-2/Bax ratio / CFU-L / drug resistance

References

[1] YueB B, ChenY. The mechanism of regrowth resistance induced by correlative genes in the treatment of leukemia. J Clin Hematol, 1996, 9: 179-179

[2] YangB E, KorsmeyerS J. Molecular thanatopsis: A discourse on the Bcl-2 family and cell death. Blood, 1996, 88: 386-386

[3] MeijerinkJ P P, SmetsersTFCM, SloetjesA W, et al. . Bax mutation in cell lines derived from hematological malignancies. Leukemia, 1995, 9: 1828-1828

[4] ChenY, ZhouJ F, YueB B, et al. . Study on Bcl-2 gene and its family genes Bax, Bcl-Xl as well as Fas/Apo-1 and their clinical significance in acute leukemia. Chin Med J, 1998, 111: 11-11